Press Releases

01-12 Alnylam Pharmaceuticals : 2026 J.P. Morgan Presentation PU
01-11 Alnylam Pharmaceuticals : Launches “ 2030” Strategy to Drive Next Era of Growth and Patient Impact PU
01-11 Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact BU
01-05 Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference BU
12-17 Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics BU
12-11 Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027 BU
12-03 Alnylam Pharmaceuticals Announces Changes to Board of Directors BU
11-08 New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM BU
11-04 Alnylam to Webcast Presentations at Upcoming November Investor Conferences BU
30/10/25 Alnylam Pharmaceuticals : Q3 2025 Earnings Presentation PU
30/10/25 Alnylam Pharmaceuticals : Q3 2025 GAAP/Non-GAAP Reconciliation › PU
30/10/25 Alnylam: Q3 Earnings Snapshot AQ
30/10/25 Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress BU
16/10/25 Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results BU
01/10/25 Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran BU
29/09/25 Alnylam Pharmaceuticals, Inc. - New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran AQ
28/09/25 New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran BU
18/09/25 Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine PR
10/09/25 Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes BU
09/09/25 Alnylam Pharmaceuticals Announces Proposed Offering of $500 Million Convertible Senior Notes AQ
08/09/25 Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes BU
01/09/25 Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial AQ
01/09/25 Genentech and Alnylam Advance Zilebesiran into Global Phase III Cardiovascular Outcomes Trial for People with Uncontrolled Hypertension AQ
01/09/25 Alnylam Pharmaceuticals - New Data from Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran's Long-Term Cardiovascular Benefit in ATTR-CM AQ
01/09/25 Roche touts 'best-in-disease' potential for anti-hypertensive zilebesiran AQ
No results for this search